Welcome to our dedicated page for Organigram Global news (Ticker: OGI), a resource for investors and traders seeking the latest updates and insights on Organigram Global stock.
Organigram Global Inc. reports developments tied to its Canadian cannabis cultivation, processing, branded adult-use products and cannabinoid beverage business. The company operates through subsidiaries including Organigram Inc., a licensed cultivator and processor, and participates in U.S. and Canadian cannabinoid beverages through Collective Project Limited.
Recurring news themes for OGI include operating and financial results, cannabis product launches, brand extensions, international partnership activity, and regulatory matters under Health Canada’s Cannabis Act and Cannabis Regulations. Company updates also cover brands such as Edison, Big Bag O’ Buds, SHRED, Monjour, Tremblant, Collective Project, Trailblazer, BOXHOT and DEBUNK; the FAST nanoemulsion technology platform; and production, edibles, extraction, packaging and fulfillment facilities in Canada.
Organigram (NASDAQ:OGI) is launching Edison and BOXHOT medical vape and pastille products in Australia, introducing 10 SKUs and shipping single‑strain live terpenes from Canada. The products will distribute via Leafio, expected to reach >4,000 pharmacies, and will debut at the United in Compassion symposium Feb 26–28.
The move expands Organigram’s non‑flower portfolio into a growing Australian medical cannabis market and highlights ready‑to‑consume formats and science‑led formulations.
Organigram (NASDAQ:OGI / TSX:OGI) announced a C$65.2 million private placement with BAT (NYSE:BTI) to help fund its acquisition of Sanity Group. BAT will subscribe for 14,027,074 shares at C$3.00 and exercise top-up rights for 9,897,356 shares at C$2.335854.
Proceeds, plus restricted cash and up to $60 million credit facilities, will fund the cash portion of the acquisition and working capital. Issuances may include non-voting preferred shares to keep BAT below a 30% voting threshold; conversion mechanics cap beneficial ownership at 49%.
Organigram (NASDAQ: OGI) agreed to acquire Berlin-based Sanity Group for upfront consideration of €113.4 million and a maximum earnout of €113.8 million, funded by cash, a credit facility and an expected C$65.2 million equity investment by BAT. Sanity reported net revenue growth from €9M (2023) to €60M (2025) and positive 2025 EBITDA.
The transaction is subject to shareholder, TSX and German foreign investment approvals and is expected to close in Q2 2026, conditional on financing and customary closing conditions.
Organigram (NASDAQ: OGI) reported Q1 Fiscal 2026 results for the quarter ended December 31, 2025, showing strong year-over-year growth. Gross revenue was $97.3M (+46% YoY) and net revenue $63.5M (+49% YoY). Adjusted EBITDA rose to $5.3M (+273% YoY). Cash and short-term investments totaled $63.0M.
Key operational highlights include a 43% increase in kilograms harvested, expanded U.S. retail footprint to 11 states, and a powdery mildew genetic screening breakthrough to improve yield stability.
Organigram (NASDAQ: OGI) will report first quarter fiscal 2026 results for the period ended December 31, 2025 on Tuesday, February 10, 2026, before market open. A conference call and live webcast are scheduled for 8:00 am Eastern Time to discuss results.
Registration is required for the call; a replay will be available within 24 hours and archived for 90 days at the company investor site.
Organigram (NASDAQ: OGI) expanded its innovation investment in Phylos with a US$3 million follow‑on advance, bringing total loan principal to US$10 million. The amended agreements grant Organigram priority access to Phylos’ autoflower genetics pipeline, including delivery of 30 next‑generation genetics twice annually through 2030 and five‑year exclusivity for chosen cultivars in international markets (Canada, Australia, UK, Germany, Israel) with options to add territories.
The loan matures on May 25, 2028 and is subject to conversion or other resolution mechanisms; annual portfolio reviews will retain exclusivity only for commercially relevant cultivars.
Organigram (NASDAQ: OGI) reported record Q4 and Fiscal 2025 results with Fiscal 2025 gross revenue $403.0M (+63% YoY) and net revenue $259.2M (+62% YoY). Adjusted gross margin was $91.0M (35%) and adjusted EBITDA was $21.9M (+160% YoY). The company maintained 11.9% Canadian recreational market share and reported record international revenue of $26.3M (+173% YoY). Cash, restricted cash and short-term investments were $84.4M at Sept 30, 2025.
Operational highlights include the Motif and Collective Project acquisitions, FAST™ launch, seed-based cultivation gains, and largest annual harvest.
Organigram (NASDAQ: OGI) will report fourth quarter fiscal 2025 results for the period ended September 30, 2025 on Tuesday, December 16, 2025 prior to market open.
The company will host a conference call on December 16, 2025 at 8:00 am Eastern Time; participants must register to receive dial-in details and unique entry codes. A live webcast link is provided and a replay will be available within 24 hours at the company investor site and archived for 90 days.
Organigram (TSX: OGI, NASDAQ: OGI) announced the appointment of James Yamanaka as Chief Executive Officer, expected to assume the role on or about January 15, 2026 and to join the board at that time. Mr. Yamanaka joins from British American Tobacco after more than 20 years in strategy and general management across Europe and Asia.
Effective December 1, 2025, Board chairman Peter Amirault will serve as interim executive chair to oversee day-to-day management, with Geoff Machum as independent lead director during the transition. The appointment is subject to customary immigration and required procedures.
Organigram (NASDAQ: OGI) released Abacus Data polling (June 25–July 2, 2025, n=2,000) showing 59% of Canadians want the federal government to do more to support jobs and innovation in the legal cannabis sector and 59% view the industry as an important part of the economy. The poll found 35% used cannabis in the past six months.
The release cites Organigram’s 2024 economic estimate: $16B direct GDP, $29B economic output, and 227,000 jobs. The company described priorities: illicit-market enforcement, lower excise taxes, and support for beverages, edibles, and wellness products.